Literature DB >> 34950177

A Novel Treatment Strategy for Patients with Intermediate-Stage HCC Who Are Not Suitable for TACE: Upfront Systemic Therapy Followed by Curative Conversion.

Masatoshi Kudo1.   

Abstract

Entities:  

Keywords:  Atezolizumab/bevacizumab curative conversion; Hepatocellular carcinoma; Intermediate-stage hepatocellular carcinoma

Year:  2021        PMID： 34950177      PMCID： PMC8647118          DOI： 10.1159/000519749

Source DB:  PubMed          Journal:  Liver Cancer        ISSN： 1664-5553            Impact factor:   11.740


× No keyword cloud information.
  12 in total

1.  A New Treatment Option for Intermediate-Stage Hepatocellular Carcinoma with High Tumor Burden: Initial Lenvatinib Therapy with Subsequent Selective TACE.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2019-09-18       Impact factor: 11.740

2.  A New Era in Systemic Therapy for Hepatocellular Carcinoma: Atezolizumab plus Bevacizumab Combination Therapy.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2020-03-05       Impact factor: 11.740

3.  Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.

Authors:  Richard S Finn; Shukui Qin; Masafumi Ikeda; Peter R Galle; Michel Ducreux; Tae-You Kim; Masatoshi Kudo; Valeriy Breder; Philippe Merle; Ahmed O Kaseb; Daneng Li; Wendy Verret; Derek-Zhen Xu; Sairy Hernandez; Juan Liu; Chen Huang; Sohail Mulla; Yulei Wang; Ho Yeong Lim; Andrew X Zhu; Ann-Lii Cheng
Journal:  N Engl J Med       Date:  2020-05-14       Impact factor: 91.245

Review 4.  Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy.

Authors:  Rakesh K Jain
Journal:  Science       Date:  2005-01-07       Impact factor: 47.728

Review 5.  Hepatocellular carcinoma.

Authors:  Josep M Llovet; Andrew Burroughs; Jordi Bruix
Journal:  Lancet       Date:  2003-12-06       Impact factor: 79.321

Review 6.  Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update.

Authors:  Masatoshi Kudo; Yusuke Kawamura; Kiyoshi Hasegawa; Ryosuke Tateishi; Kazuya Kariyama; Shuichiro Shiina; Hidenori Toyoda; Yasuharu Imai; Atsushi Hiraoka; Masafumi Ikeda; Namiki Izumi; Michihisa Moriguchi; Sadahisa Ogasawara; Yasunori Minami; Kazuomi Ueshima; Takamichi Murakami; Shiro Miyayama; Osamu Nakashima; Hirohisa Yano; Michiie Sakamoto; Etsuro Hatano; Mitsuo Shimada; Norihiro Kokudo; Satoshi Mochida; Tetsuo Takehara
Journal:  Liver Cancer       Date:  2021-05-19       Impact factor: 11.740

7.  Lenvatinib-Transarterial Chemoembolization Sequential Therapy as an Effective Treatment at Progression during Lenvatinib Therapy for Advanced Hepatocellular Carcinoma.

Authors:  Yusuke Kawamura; Masahiro Kobayashi; Junichi Shindoh; Yuta Kobayashi; Satoshi Okubo; Licht Tominaga; Akira Kajiwara; Kayoko Kasuya; Soichi Iritani; Shunichiro Fujiyama; Tetsuya Hosaka; Satoshi Saitoh; Hitomi Sezaki; Norio Akuta; Fumitaka Suzuki; Yoshiyuki Suzuki; Kenji Ikeda; Yasuji Arase; Masaji Hashimoto; Tokuyo Kozuka; Hiromitsu Kumada
Journal:  Liver Cancer       Date:  2020-10-30       Impact factor: 11.740

8.  Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial.

Authors:  Masatoshi Kudo; Kazuomi Ueshima; Masafumi Ikeda; Takuji Torimura; Nobukazu Tanabe; Hiroshi Aikata; Namiki Izumi; Takahiro Yamasaki; Shunsuke Nojiri; Keisuke Hino; Hidetaka Tsumura; Teiji Kuzuya; Norio Isoda; Kohichiroh Yasui; Hajime Aino; Akio Ido; Naoto Kawabe; Kazuhiko Nakao; Yoshiyuki Wada; Osamu Yokosuka; Kenichi Yoshimura; Takuji Okusaka; Junji Furuse; Norihiro Kokudo; Kiwamu Okita; Philip James Johnson; Yasuaki Arai
Journal:  Gut       Date:  2019-12-04       Impact factor: 23.059

Review 9.  Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference.

Authors:  Josep M Llovet; Augusto Villanueva; Jorge A Marrero; Myron Schwartz; Tim Meyer; Peter R Galle; Riccardo Lencioni; Tim F Greten; Masatoshi Kudo; Sumithra J Mandrekar; Andrew X Zhu; Richard S Finn; Lewis R Roberts
Journal:  Hepatology       Date:  2020-09-09       Impact factor: 17.425

10.  Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child-Pugh A Liver Function: A Proof-Of-Concept Study.

Authors:  Masatoshi Kudo; Kazuomi Ueshima; Stephan Chan; Tomohiro Minami; Hirokazu Chishina; Tomoko Aoki; Masahiro Takita; Satoru Hagiwara; Yasunori Minami; Hiroshi Ida; Mamoru Takenaka; Toshiharu Sakurai; Tomohiro Watanabe; Masahiro Morita; Chikara Ogawa; Yoshiyuki Wada; Masafumi Ikeda; Hiroshi Ishii; Namiki Izumi; Naoshi Nishida
Journal:  Cancers (Basel)       Date:  2019-07-31       Impact factor: 6.639
View more
  5 in total

1.  Combination Immunotherapy with Anti-PD-1/PD-L1 Antibody plus Anti-VEGF Antibody May Promote Cytotoxic T Lymphocyte Infiltration in Hepatocellular Carcinoma, Including in the Noninflamed Subclass.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2022-05-10       Impact factor: 12.430

Review 2.  Trial Designs for Integrating Novel Therapeutics into the Management of Intermediate-Stage Hepatocellular Carcinoma.

Authors:  Yung-Yeh Su; Yi-Sheng Liu; Chin-Fu Hsiao; Chiun Hsu; Li-Tzong Chen
Journal:  J Hepatocell Carcinoma       Date:  2022-06-02

Review 3.  New treatment paradigm with systemic therapy in intermediate-stage hepatocellular carcinoma.

Authors:  Masatoshi Kudo
Journal:  Int J Clin Oncol       Date:  2022-05-08       Impact factor: 3.850

4.  Atezolizumab plus Bevacizumab Followed by Curative Conversion (ABC Conversion) in Patients with Unresectable, TACE-Unsuitable Intermediate-Stage Hepatocellular Carcinoma.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2022-07-27       Impact factor: 12.430

Review 5.  Transarterial Chemoembolization for Hepatocellular Carcinoma: Why, When, How?

Authors:  Evgenia Kotsifa; Chrysovalantis Vergadis; Michael Vailas; Nikolaos Machairas; Stylianos Kykalos; Christos Damaskos; Nikolaos Garmpis; Georgios D Lianos; Dimitrios Schizas
Journal:  J Pers Med       Date:  2022-03-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.